Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 1 of 2: GR values. - Dataset (ID:20364)
Download: Excel (XLSX), Comma-separated (CSV)
Cell line | Drug name | Experimental replicate | Timepoint | Drug concentration | Live cell count | Average live cell count, DMSO control | Average live cell count (time = 0) | Log10(drug concentration) | GR value | Relative cell count (treatment versus DMSO) | Cell doublings (DMSO control) | Experiment name |
---|---|---|---|---|---|---|---|---|---|---|---|---|
HCC70 | BX-912 | 1 | 72 | 3.2 | 884.5 | 3461.8 | 1279.8 | 0.505 | -0.227 | 0.256 | 1.436 | HCC70 BX912 0 1 72 |
HCC70 | BX-912 | 1 | 72 | 0.1 | 3498.3 | 3461.8 | 1279.8 | -1.0 | 1.010 | 1.010 | 1.436 | HCC70 BX912 0 1 72 |
HCC70 | BX-912 | 1 | 72 | 1.0 | 2480.5 | 3461.8 | 1279.8 | 0.0 | 0.586 | 0.717 | 1.436 | HCC70 BX912 0 1 72 |
HCC70 | BX-912 | 1 | 72 | 0.01 | 3606.5 | 3461.8 | 1279.8 | -2.0 | 1.060 | 1.040 | 1.436 | HCC70 BX912 0 1 72 |
HCC70 | BX-912 | 1 | 72 | 0.32 | 3442.0 | 3461.8 | 1279.8 | -0.495 | 0.992 | 0.994 | 1.436 | HCC70 BX912 0 1 72 |
HCC70 | BX-912 | 1 | 72 | 0.032 | 3679.5 | 3461.8 | 1279.8 | -1.49 | 1.090 | 1.060 | 1.436 | HCC70 BX912 0 1 72 |
HCC38 | Everolimus | 3 | 72 | 1.0 | 2136.3 | 3195.8 | 1180.5 | 0.0 | 0.511 | 0.668 | 1.437 | HCC38 Everolimus 0 3 72 |
HCC38 | Everolimus | 3 | 72 | 3.2 | 2141.0 | 3195.8 | 1180.5 | 0.505 | 0.513 | 0.670 | 1.437 | HCC38 Everolimus 0 3 72 |
HCC38 | GDC-0980 | 3 | 72 | 0.1 | 2726.5 | 3196.0 | 1180.5 | -1.0 | 0.791 | 0.853 | 1.437 | HCC38 GDC0980 0 3 72 |
HCC38 | GDC-0980 | 3 | 72 | 0.32 | 2106.5 | 3196.0 | 1180.5 | -0.495 | 0.496 | 0.659 | 1.437 | HCC38 GDC0980 0 3 72 |
HCC38 | GDC-0980 | 3 | 72 | 1.0 | 1673.0 | 3196.0 | 1180.5 | 0.0 | 0.275 | 0.523 | 1.437 | HCC38 GDC0980 0 3 72 |
HCC38 | GDC-0980 | 3 | 72 | 0.032 | 3103.0 | 3196.0 | 1180.5 | -1.49 | 0.959 | 0.971 | 1.437 | HCC38 GDC0980 0 3 72 |
HCC38 | GDC-0980 | 3 | 72 | 0.0032 | 3162.3 | 3196.0 | 1180.5 | -2.49 | 0.985 | 0.989 | 1.437 | HCC38 GDC0980 0 3 72 |
HCC38 | GDC-0980 | 3 | 72 | 0.01 | 3186.0 | 3196.0 | 1180.5 | -2.0 | 0.996 | 0.997 | 1.437 | HCC38 GDC0980 0 3 72 |
HCC38 | GDC-0980 | 3 | 72 | 3.2 | 1148.5 | 3196.0 | 1180.5 | 0.505 | -0.019 | 0.359 | 1.437 | HCC38 GDC0980 0 3 72 |
HCC38 | Everolimus | 3 | 72 | 0.032 | 2320.3 | 3195.8 | 1180.5 | -1.49 | 0.601 | 0.726 | 1.437 | HCC38 Everolimus 0 3 72 |
HCC38 | Everolimus | 3 | 72 | 0.001 | 2398.8 | 3195.8 | 1180.5 | -3.0 | 0.638 | 0.751 | 1.437 | HCC38 Everolimus 0 3 72 |
HCC38 | Everolimus | 3 | 72 | 0.0032 | 2322.3 | 3195.8 | 1180.5 | -2.49 | 0.601 | 0.727 | 1.437 | HCC38 Everolimus 0 3 72 |
HCC38 | Everolimus | 3 | 72 | 0.1 | 2233.8 | 3195.8 | 1180.5 | -1.0 | 0.559 | 0.699 | 1.437 | HCC38 Everolimus 0 3 72 |
HCC38 | Everolimus | 3 | 72 | 0.01 | 2332.8 | 3195.8 | 1180.5 | -2.0 | 0.607 | 0.730 | 1.437 | HCC38 Everolimus 0 3 72 |
HCC38 | GDC-0980 | 3 | 72 | 0.001 | 3115.0 | 3196.0 | 1180.5 | -3.0 | 0.965 | 0.975 | 1.437 | HCC38 GDC0980 0 3 72 |
HCC38 | Everolimus | 3 | 72 | 0.32 | 2197.3 | 3195.8 | 1180.5 | -0.495 | 0.541 | 0.688 | 1.437 | HCC38 Everolimus 0 3 72 |
HCC38 | Torin1 | 3 | 72 | 0.032 | 1952.3 | 3204.3 | 1180.5 | -1.49 | 0.418 | 0.609 | 1.441 | HCC38 Torin1 0 3 72 |
HCC38 | Torin1 | 3 | 72 | 0.1 | 1495.0 | 3204.3 | 1180.5 | -1.0 | 0.178 | 0.467 | 1.441 | HCC38 Torin1 0 3 72 |
HCC38 | Torin1 | 3 | 72 | 0.32 | 1196.8 | 3204.3 | 1180.5 | -0.495 | 0.010 | 0.373 | 1.441 | HCC38 Torin1 0 3 72 |